Table 3. Treatment modalities for each patient included in the retrospective chart analysis.
| Tecfidera™ (n=51) |
Control (n=53) |
|||
|---|---|---|---|---|
| Females (n=39) | Males (n=12) | Females (n=40) | Males (n=13) | |
| Average # of drugs before Tecfidera™ |
1.92 ± 1.46 |
2.08 ± 1.78 |
n/a^ |
n/a |
| Average # of drugs |
n/a |
n/a |
1.78 ± 0.89 |
1.69 ± 0.75 |
| Number of patients taking each of the following drugs | ||||
| None or IVS* |
3 |
1 |
1 |
0 |
| Interferon β-1a |
24 |
7 |
12 |
5 |
| Interferon β-1b |
8 |
3 |
4 |
1 |
| Glatiramer acetate |
24 |
7 |
37 |
13 |
| Fingolimod |
6 |
2 |
6 |
1 |
| Teriflunomide |
0 |
0 |
5 |
0 |
| Mitoxantron |
1 |
1 |
0 |
0 |
| Natalizumab |
4 |
1 |
4 |
1 |
| Ocrelizumab |
0 |
0 |
1 |
1 |
| Alemtuzumab |
0 |
0 |
0 |
0 |
| Glatiramer acetate + IVS* |
4 |
0 |
0 |
0 |
| Cladribine |
1 |
0 |
0 |
0 |
| Interferon β-1b + IVS* |
1 |
1 |
0 |
0 |
| CCT + Interferon β-1b + IVS* |
1 |
1 |
0 |
0 |
| Interferon β-1a + IVS* |
0 |
1 |
0 |
0 |
| Intravenous Immunoglobulin |
0 |
1 |
0 |
0 |
| Laquinimab | 0 | 0 | 1 | 0 |
* Intravenous steroids, Interferon β-1α: Avonex, Plegridy, Rebif, ^ not applicable